Clinical Trials Logo

Multiple Myeloma (MM) clinical trials

View clinical trials related to Multiple Myeloma (MM).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04721002 Completed - Clinical trials for Multiple Myeloma (MM)

Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)

MEDICI
Start date: July 7, 2021
Phase:
Study type: Observational

Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter after each line of treatment. This is a study to assess t(11;14) and BCL2 expression in adult participants with newly diagnosed and relapsed/refractory (R/R) MM. Approximately 500 adult participants with newly confirmed or relapsed/refractory (R/R) multiple myeloma (MM) will be enrolled in around 15-20 countries. Participants will receive standard of care while participating in this study. No drug will be administered as a part of this study. Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide bone marrow and blood samples.

NCT ID: NCT02920697 Completed - Clinical trials for Multiple Myeloma (MM)

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Start date: March 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety profile and tolerability of S 55746 in patients with CLL, B-Cell NHL and MM, in terms of Dose-Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD) and determine the Recommended Phase 2 Dose (RP2D) through safety profile (DLT, MTD), PK profile, PD profile and preliminary efficacy.

NCT ID: NCT02265731 Completed - Clinical trials for Acute Myeloid Leukemia (AML)

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Start date: September 22, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This study is evaluating the safety, pharmacokinetic profile and efficacy of venetoclax under a once daily dosing schedule in Japanese participants with hematological malignancies.

NCT ID: NCT02211014 Completed - Clinical trials for Multiple Myeloma (MM)

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

Start date: February 2015
Phase: Phase 1
Study type: Interventional

To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)

NCT ID: NCT01413568 Completed - Clinical trials for Myelodysplastic Syndrome (MDS)

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies

Start date: April 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Determine the safety and tolerability of POL6326 when used as a single mobilization agent.

NCT ID: NCT00889798 Completed - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Tumor Registry of Lymphatic Neoplasia

TLN-Registry
Start date: April 2009
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.

NCT ID: NCT00710528 Completed - Clinical trials for Acute Myeloid Leukemia (AML)

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.